Illumina - Stock Price History | ILMN

Historical daily share price chart and data for Illumina since 2021 adjusted for splits. The latest closing stock price for Illumina as of October 22, 2021 is 409.15.
  • The all-time high Illumina stock closing price was 524.84 on August 16, 2021.
  • The Illumina 52-week high stock price is 555.77, which is 35.8% above the current share price.
  • The Illumina 52-week low stock price is 288.01, which is 29.6% below the current share price.
  • The average Illumina stock price for the last 52 weeks is 413.58.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Illumina Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 325.3142 327.0000 400.7400 209.2000 370.0000 11.53%
2019 309.8041 294.5200 378.2300 266.8400 331.7400 10.61%
2018 286.5595 224.0300 367.0600 209.5400 299.9300 37.27%
2017 185.7857 131.1300 230.0300 131.1300 218.4900 70.64%
2016 151.5358 181.2800 186.1700 122.0200 128.0400 -33.29%
2015 191.9747 185.4200 240.0200 140.1700 191.9450 3.99%
2014 164.5656 110.3400 194.3300 108.6100 184.5800 66.90%
2013 72.8981 55.4200 110.5900 48.3600 110.5900 98.94%
2012 46.2589 31.7300 56.3900 31.4300 55.5900 82.38%
2011 56.3635 64.3400 77.8800 25.9600 30.4800 -51.88%
2010 45.4461 30.5500 65.5000 30.3500 63.3400 106.45%
2009 34.5958 26.8500 43.7400 23.4300 30.6800 17.77%
2008 35.7914 29.7800 47.0450 19.8300 26.0500 -12.08%
2007 21.6625 19.2050 31.1900 14.4300 29.6300 50.75%
2006 15.5177 7.4050 22.8450 7.4050 19.6550 178.79%
2005 5.8197 4.6350 8.3400 3.3850 7.0500 48.73%
2004 3.4494 3.5350 4.8500 2.1400 4.7400 34.47%
2003 1.9504 1.6400 4.2500 0.9000 3.5250 109.20%
2002 2.9803 5.6250 6.1700 1.4550 1.6850 -71.34%
2001 5.3563 7.6250 10.8750 2.9375 5.8800 -26.77%
2000 16.7712 19.5850 23.3150 8.0000 8.0300 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $60.022B $3.239B
Illumina, Inc. is improving human health by unlocking the power of the genome. Their focus on innovation has established them as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Their products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76